Literature DB >> 8191784

Expression of soluble forms of rubella virus glycoproteins in mammalian cells.

T C Hobman1, N O Seto, S Gillam.   

Abstract

Rubella virus (RV) virions contain two envelope glycoproteins, E1 and E2. Removal of hydrophobic regions in their carboxyl termini by genetic engineering caused them to be secreted rather than maintained in cell membranes of transfected COS cells. Truncated E2 was secreted in the absence of E1, whereas E1 lacking its transmembrane domain required coexpression of E2 for export from the cell. Secreted E2 was found to contain both O-linked and N-linked complex glycans, whereas secreted E1 retained virus neutralization and hemagglutination epitopes, suggesting the possibility of using soluble RV antigens as subunit vaccines and for serodiagnostic purposes. Stable Chinese hamster ovary cell lines secreting RV E1 were constructed for large scale preparation of recombinant E1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191784      PMCID: PMC7133988          DOI: 10.1016/0168-1702(94)90022-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  33 in total

1.  Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum.

Authors:  T Nilsson; M Jackson; P A Peterson
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

2.  Role of N-linked oligosaccharides in processing and intracellular transport of E2 glycoprotein of rubella virus.

Authors:  Z Qiu; T C Hobman; H L McDonald; N O Seto; S Gillam
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Nucleotide sequence of the genes coding for the membrane glycoproteins E1 and E2 of rubella virus.

Authors:  G Vidgren; K Takkinen; N Kalkkinen; L Kääriäinen; R F Pettersson
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

4.  Expression from cloned cDNA of cell-surface secreted forms of the glycoprotein of vesicular stomatitis virus in eucaryotic cells.

Authors:  J K Rose; J E Bergmann
Journal:  Cell       Date:  1982-10       Impact factor: 41.582

5.  Immunochemical identification of rubella virus hemagglutinin.

Authors:  M N Waxham; J S Wolinsky
Journal:  Virology       Date:  1983-04-15       Impact factor: 3.616

6.  The influence of N-linked glycosylation on the antigenicity and immunogenicity of rubella virus E1 glycoprotein.

Authors:  Z Qiu; F Tufaro; S Gillam
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

7.  A bio-engineered rubella E1 antigen.

Authors:  G M Terry; L Ho-Terry; P Londesborough; K R Rees
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

8.  Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum.

Authors:  M R Jackson; T Nilsson; P A Peterson
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

9.  A specific transmembrane domain of a coronavirus E1 glycoprotein is required for its retention in the Golgi region.

Authors:  C E Machamer; J K Rose
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

10.  Processing and intracellular transport of rubella virus structural proteins in COS cells.

Authors:  T C Hobman; M L Lundstrom; S Gillam
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

View more
  3 in total

1.  Interactions between rubella virus capsid and host protein p32 are important for virus replication.

Authors:  Martin D Beatch; Jason C Everitt; LokMan J Law; Tom C Hobman
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Effects of mutations in the rubella virus E1 glycoprotein on E1-E2 interaction and membrane fusion activity.

Authors:  D Yang; D Hwang; Z Qiu; S Gillam
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

3.  Targeting of a heterodimeric membrane protein complex to the Golgi: rubella virus E2 glycoprotein contains a transmembrane Golgi retention signal.

Authors:  T C Hobman; L Woodward; M G Farquhar
Journal:  Mol Biol Cell       Date:  1995-01       Impact factor: 4.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.